CLINICAL_TRIALS
trial_result
· 2023-08-04
Clinical Trial Update: A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma [Phase 2]
Summary
Phase II study of AT7519M, a CDK inhibitor, in patients with relapsed mantle cell lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: NCIC Clinical Trials Group | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED